Skip to main content

News

A4 Study Releases Negative Results

By Carousel Slider, Commentary, In the News, UCI MIND

The topline results for the Anti-Amyloid treatment in Asymptomatic Alzheimer’s disease (A4) study were released today (https://a4study.org). Unfortunately, the drug being investigated, solanezumab, failed to demonstrate a benefit in slowing memory changes in a population of individuals age 65-to-85 who met criteria for preclinical Alzheimer’s disease. Preclinical Alzheimer’s is a relatively new construct. It includes people who are older and have normal memory performance, but in whom biological tests suggest that the risk for Alzheimer’s disease dementia is high. The A4 study was among the first ever preclinical AD trials, boldly blazing a trail that has now been followed by…

The post A4 Study Releases Negative Results appeared first on UCI MIND.

Read More

UCI faculty member awarded grant to study patient reactions to Alzheimer’s disease diagnoses

By Carousel Slider, In the News, UCI MIND

Dr. Joshua Grill and colleagues at the University of Pittsburgh have been awarded a 3.5 million dollar grant by the National Institute on Aging to advance the field’s understanding of real-world patient and family member reactions to biomarker-informed Alzheimer’s disease and related disorders (ADRD) diagnoses and to provide critical information for directing post-diagnostic resources to monitor and support those most in need. Read the full news story about this important research here  

The post UCI faculty member awarded grant to study patient reactions to Alzheimer’s disease diagnoses appeared first on UCI MIND.

Read More

No change in coverage yet for monoclonal antibody treatments for Alzheimer’s disease

By Carousel Slider, Commentary, In the News, UCI MIND

On February 17, 2023, a bipartisan group of Senators sent the Secretary of Health and Human Services, Javier Baccera, and the Administrator of the Centers for Medicare and Medicaid Services (CMS), Chiquita Brooks-LaSure, a letter requesting that CMS reconsider their decision to require Coverage with Evidence Determination (CED) that was levied after the accelerated approval of aducanumab. The letter followed a similar request from the Alzheimer’s Association, made in December 2022. The CED decision significantly limited access to aducanumab and other monoclonal antibodies (should they be approved), requiring that coverage would be granted only if Medicare beneficiaries were enrolled in…

The post No change in coverage yet for monoclonal antibody treatments for Alzheimer’s disease appeared first on UCI MIND.

Read More

The family of Bruce Willis shared that he has FTD, what’s that?

By Carousel Slider, Commentary, In the News, UCI MIND

Frontotemporal dementia (FTD) is a form of dementia that typically affects individuals in their 50s and 60s. It is therefore, commonly referred to as young onset dementia. Clinically, FTD can present in two ways; some patients present with behavioral impairment and are referred to as behavioral variant FTD (bvFTD). The other main presentation involves language decline and is called primary progressive aphasia (PPA). Both conditions start insidiously and accurate diagnosis can be a challenge, especially at early stages of the disease. In bvFTD, patients can present with apathy, lack of empathy, increased appetite, preference for sweet tooth, new onset of…

The post The family of Bruce Willis shared that he has FTD, what’s that? appeared first on UCI MIND.

Read More

Support from Joan and Don Beall will sustain two UCI MIND programs

By Carousel Slider, In the News, UCI MIND

Irvine, Calif., Jan. 31, 2023 — Sustained support from philanthropists Joan and Don Beall to the the Institute for Memory Impairments and Neurological Disorders will allow for the continuation of an educational outreach program in Orange County high schools and the creation of a new research award for an early career researcher. “We are grateful for the Beall’s leadership, involvement and increased support of $100,000 a year for our educational and research programs,” said Joshua Grill, director of UCI MIND. “Support like theirs is critical to the institute’s mission and demonstrates the trust and commitment of the local community in…

The post Support from Joan and Don Beall will sustain two UCI MIND programs appeared first on UCI MIND.

Read More

UCI MIND Faculty leads study to model sporadic Alzheimer’s disease in degus

By Carousel Slider, In the News, UCI MIND

UCI School of Medicine highlighted innovative research performed in the lab of Xiangmin Xu, PhD, UCI MIND faculty member and professor and Chancellor’s Fellow of anatomy and neurobiology in the UCI School of Medicine.  Dr. Xu and colleagues have found that sporadic Alzheimer’s disease can be modeled in a non-murine rodent called the Chilean degu. “Our findings, taken together, show spontaneous AD-like correlative phenotypes in cognitive performance and neuropathology in aged, outbred degus. This supports that aged degus are a useful and practical model of natural sporadic AD.” Xiangmin Xu Read the article in the February edition of the UCI School…

The post UCI MIND Faculty leads study to model sporadic Alzheimer’s disease in degus appeared first on UCI MIND.

Read More

FDA decides not to grant accelerated approval to donanemab

By Carousel Slider, Commentary, In the News, UCI MIND

In a somewhat surprising move, the US Food and Drug Administration (FDA) has declined to grant accelerated approval to Eli Lilly’s donanemab Read the full press release from Eli Lilly here Like aducanumab and lecanemab, which were previously granted accelerated approval by the FDA, donanemab is a monoclonal antibody treatment against the beta amyloid protein that accumulates in the brain of a person with Alzheimer’s disease. Eli Lilly published very promising results for donanemab in 2021, which included demonstration that donanemab could lower amyloid levels in the brain of people with mild cognitive impairment and mild dementia (the basis for…

The post FDA decides not to grant accelerated approval to donanemab appeared first on UCI MIND.

Read More

Healthy, Drug-Resistant Microglia Reinvigorate Mouse Brain

By Carousel Slider, In the News, UCI MIND

UCI MIND faculty member and professor, Mathew Blurton-Jones, PhD, is featured in AlzForum for his lab’s recent collaborative work on creating a new strain of resistant microglia. Lead author and graduate student in the Blurton-Jones lab, Jean Paul Chadarevian, along with collaborators at the University of Pennsylvania published their innovative work in Journal of Experimental Medicine in the December 2022 issue. Read the full article here >

The post Healthy, Drug-Resistant Microglia Reinvigorate Mouse Brain appeared first on UCI MIND.

Read More

Alzheimer’s research in people with Down syndrome benefits all

By Carousel Slider, Commentary, In the News, UCI MIND

UCI MIND Faculty Member Elizabeth Head, PhD was featured in the Akron Beacon Journal: I recently interviewed Dr. Elizabeth Head, a [professor and] neuropathology core co-investigator at the Alzheimer’s Disease Research Center at University of California, Irvine. While she collaborates with researchers studying Alzheimer’s in the general population, her research is focused specifically on the Down syndrome population. Her team and others are conducting longitudinal studies, in which volunteers with Down syndrome participate for many years, discovering relevant data that are the building blocks for future treatments. Read the full article here >

The post Alzheimer’s research in people with Down syndrome benefits all appeared first on UCI MIND.

Read More

Two New Stabs at Vaccinating People Against Pathologic Tau

By Carousel Slider, Commentary, In the News, UCI MIND

The work of our faculty, researchers, and collaborators was highlighted in a recent Alzforum article on anti-tau vaccines. AC Immune updates Phase 1b/2 comparison of two anti-#tau vaccines. A liposomal vaccine prompted #antibody response against phospho-tau. Preclinical data bode well for another tau vaccine; first trial slated for next year. Read more >

The post Two New Stabs at Vaccinating People Against Pathologic Tau appeared first on UCI MIND.

Read More
English